Cardioprotective agents
The invention relates to pharmaceutical compositions comprising 5-Methoxytryptamine or a salt thereof for the prevention and/or treatment of mammalian cardiac tissue damage. 5-Methoxytryptamine and the salts thereof act as free radical scavengers in the prevention and/or treatment of mammalian cardiac tissue damage mediated by free oxygen radicals.
1 . A composition comprising 5-methoxytryptamine or its a pharmaceutically acceptable salt and a carrier, excipient or additive; said 5-methoxytryptamine present in an amount effective to prevent, reduce or treat mammalian tissue damage.
2 . The composition as claimed in claim 1 is a form selected from the group consisting of a tablet, capsule, powder, lozenge, solution, syrup, aqueous or oily suspension, elixir, implant, and aqueous or non-aqueous injection.
3 . The composition as claimed in claim 1 , wherein the amount of 5-methoxy tryptamine or its salt is from 5 to 500 mg.
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . A composition comprising 5-methoxytryptamine or its pharmaceutically acceptable salt and a carrier, excipient or additive.
8 . The composition as claimed in claim 7 is a form selected from the group consisting of a tablet, capsule, powder, lozenge, solution, syrup, aqueous or oily suspension, elixir, implant, and aqueous or non-aqueous injection.
9 . The composition as claimed in claim 7 , wherein the amount of 5-Methoxy tryptamine or its salt is ranges from 5 to 500 mg.
10 . A method for preventing tissue damage caused by exposure to an oxygen reactive species, comprising administering an amount of 5-Methoxytryptamine or a salt thereof effective to prevent tissue damage.
11 . (canceled)
12 . The method of claim 10 , wherein the amount of 5-methoxytryptamine or its salt is 0.7 to 7.0 mg/kg body weight.
13 . A method for treating tissue damage caused by exposure to an oxygen reactive species, comprising administering an amount of 5-Methoxytryptamine or a salt thereof effective to treat tissue damage to a patient in need thereof
14 . (canceled)
15 . The method of claim 13 , wherein the amount of 5-Methoxytryptamine or its salt is 0.7 to 7.0 mg/kg body weight.
16 . A method for treating cardiac toxicity, myocardial ischemia, myocardial infarction or heart failure comprising administering an effective amount of 5-Methoxytryptamine or a salt thereof to a patient in need thereof.
17 . The method according to claim 16 , wherein the cardiac toxicity is induced by an anthracycline antineoplastic.
18 . The method of claim 16 , wherein the amount of 5-methoxytryptamine or its salt is 0.7 to 7.0 mg/kg body weight.
19 . A method for increasing the activity of superoxide dismutase enzyme in a tissue of a patient comprising administering to the patient an amount of 5-Methoxytryptamine or a salt thereof effective to increase the activity of superoxide dismutase enzyme.
20 . (canceled)
21 . A method for treating cardiac toxicity, myocardial ischemia, mycocardial infarction or heart failure comprising administration of an amount of 5-Methoxy tryptamine or a salt thereof effective to increase the activity of superoxide dismutase enzyme to a patient in need of such treatment.
22 . A method for inhibiting lipid peroxidation in a tissue of a patient comprising administering to the patient an amount of 5-Methoxytryptamine or a salt thereof effective to inhibit the lipid peroxidation.
23 . (canceled)
24 . A method for treating cardiac toxicity, myocardial ischemia, mycocardial infarction or heart failure comprising administration of an amount of 5-Methoxytryptamine or a salt thereof effective to inhibit lipid peroxidation to a patient in need of such treatment.
25 . A method for reducing levels of creatine kinase-MB in a tissue of a patient comprising administering to the patient an amount of 5-Methoxytryptamine or a salt thereof effective to reduce the level of creatine kinase-MB.
26 . (canceled)
27 . A method for reducing levels of lactate dehydrogenase in a tissue of a patient comprising administering to the patient an amount of 5-Methoxy tryptamine or a salt thereof effective to reduce the level of lactate dehydrogenase.
28 . (canceled)
29 . (canceled)
30 . (canceled)
31 . (canceled)
32 . The method according to claim 27 , wherein the tissue is myocardium, liver, kidney, intestine, pancreas or brain.
33 . The method according to claim 10 , wherein the 5-methoxytryptamine or the pharmaceutically acceptable salt thereof is administered in a composition comprising 5-methoxytryptamine or the pharmaceutically acceptable salt and a carrier, excipient or additive.
34 . The method according to claim 33 , wherein the composition is in a form selected from the group consisting of a tablet, capsule, powder, lozenge, solution, syrup, aqueous or oily suspension, elixir, implant, and aqueous or non-aqueous injection.
35 . The method according to claim 33 , wherein the amount of 5-methoxy tryptamine or the salt in the composition is from 5 to 500 mg.
36 . The method according to claim 13 , wherein the 5-methoxytryptamine or the pharmaceutically acceptable salt is administered in a composition comprising 5-methoxytryptamine or the pharmaceutically acceptable salt and a carrier, excipient or additive.
37 . The method according to claim 36 , wherein the composition is in a form selected from the group consisting of a tablet, capsule, powder, lozenge, solution, syrup, aqueous or oily suspension, elixir, implant, and aqueous or non-aqueous injection.
38 . The method according to claim 36 , wherein the amount of 5-methoxy tryptamine or the salt in the composition is from 5 to 500 mg.
39 . The method according to claim 16 , wherein the 5-methoxytryptamine or its pharmaceutically acceptable salt is administered in a composition comprising 5-methoxytryptamine or the pharmaceutically acceptable salt and a carrier, excipient or additive.
40 . The method according to claim 39 , wherein the composition is in a form selected from the group consisting of a tablet, capsule, powder, lozenge, solution, syrup, aqueous or oily suspension, elixir, implant, and aqueous or non-aqueous injection.
41 . The method according to claim 39 , wherein the amount of 5-methoxy tryptamine or the salt in the composition is from 5 to 500 mg.
42 . The method according to claim 16 , wherein the cardiac toxicity, myocardial ischemia, myocardial infarction or heart failure is treated by reducing levels of creatine kinase-MB in the cardiac tissue of the patient by administering to the patient an amount of 5-Methoxytryptamine or the salt thereof effective to reduce the level of creatine kinase-MB.